A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYALaurie H. Sehn, Umberto Vitolo, Christopher R. Bolen et al.|Journal of Hematology & Oncology|2020Cited by 144
Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell LymphomaLaurie H. Sehn, Umberto Vitolo, Maurizio Martelli et al.|Blood|2019Cited by 11